{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:15:01Z","timestamp":1790727301425,"version":"4.1.0"},"reference-count":28,"publisher":"Society of Nuclear Medicine","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.2967\/jnumed.119.237768","type":"journal-article","created":{"date-parts":[[2019,12,20]],"date-time":"2019-12-20T21:35:26Z","timestamp":1576877726000},"page":"821-826","source":"Crossref","is-referenced-by-count":86,"title":["Hyperprogressive Disease in Patients with Non\u2013Small Cell Lung Cancer Treated with Checkpoint Inhibitors: The Role of\n                    <sup>18<\/sup>\n                    F-FDG PET\/CT"],"prefix":"10.2967","volume":"61","author":[{"given":"Angelo","family":"Castello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Mazziotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Toschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Egesta","family":"Lopci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2019,12,20]]},"reference":[{"key":"2021051712145252000_61.6.821.1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060"},{"key":"2021051712145252000_61.6.821.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082"},{"key":"2021051712145252000_61.6.821.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503093"},{"key":"2021051712145252000_61.6.821.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1507643"},{"key":"2021051712145252000_61.6.821.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1602252"},{"key":"2021051712145252000_61.6.821.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1510665"},{"key":"2021051712145252000_61.6.821.7","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00561-4"},{"key":"2021051712145252000_61.6.821.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1411087"},{"key":"2021051712145252000_61.6.821.9","doi-asserted-by":"crossref","first-page":"E2674","DOI":"10.3390\/ijms20112674","article-title":"Hyperprogression under immunotherapy","volume":"20","author":"Frelaut","year":"2019","journal-title":"Int J Mol Sci."},{"key":"2021051712145252000_61.6.821.10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1741"},{"key":"2021051712145252000_61.6.821.11","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1001\/jamaoncol.2018.3676","article-title":"Hyperprogressive disease in patients with advanced non-small cell lung cancer treated with PD-1\/PD-L1 inhibitors or with single-agent chemotherapy","volume":"4","author":"Ferrara","year":"2018","journal-title":"JAMA Oncol."},{"key":"2021051712145252000_61.6.821.12","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann Oncol."},{"key":"2021051712145252000_61.6.821.13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1390"},{"key":"2021051712145252000_61.6.821.14","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3133"},{"key":"2021051712145252000_61.6.821.15","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-016-3425-2"},{"key":"2021051712145252000_61.6.821.16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00259-017-3806-1","article-title":"Metabolic activity by 18F-FDG-PET\/CT is predictive of early response after nivolumab in previously treated NSCLC","volume":"45","author":"Kaira","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712145252000_61.6.821.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2021051712145252000_61.6.821.18","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol."},{"key":"2021051712145252000_61.6.821.19","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2961-x"},{"key":"2021051712145252000_61.6.821.20","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1007\/s00259-018-3988-1","article-title":"Is it time to change our vision of tumor metabolism prior to immunotherapy?","volume":"5","author":"Grizzi","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2021051712145252000_61.6.821.21","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the Lung Immune Prognostic Index with immune checkpoint inhibitor outcomes in patients with advanced non\u2013small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol."},{"key":"2021051712145252000_61.6.821.22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1110352"},{"key":"2021051712145252000_61.6.821.23","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1007\/s00262-019-02387-9","article-title":"Independent expression of circulating and tissue levels of PD-L1: correlation of clusters with tumor metabolism and outcome in patients with non-small cell lung cancer","volume":"68","author":"Grizzi","year":"2019","journal-title":"Cancer Immunol Immunother."},{"key":"2021051712145252000_61.6.821.24","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1002\/cncr.31999","article-title":"Hyperprogressive disease in early-phase immunotherapy trials: clinical predictors and association with immune-related toxicities\u2014hyperprogressive disease immunotherapy","volume":"125","author":"Kanjanapan","year":"2019","journal-title":"Cancer."},{"key":"2021051712145252000_61.6.821.25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1822001116"},{"key":"2021051712145252000_61.6.821.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613493"},{"key":"2021051712145252000_61.6.821.27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801946"},{"key":"2021051712145252000_61.6.821.28","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.119.237768","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T16:49:13Z","timestamp":1621270153000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.119.237768"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,20]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6,4]]},"published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.2967\/jnumed.119.237768"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.119.237768","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,20]]}}}